Neoadjuvant chemotherapy for gastric cancer with UFT

Y. Nio, M. Kawaguchi, M. Yagi, M. Takeuchi, M. Imamura, S. Teramura, M. Murakami, Y. Nishiyama, M. Fukumoto

Research output: Contribution to journalArticlepeer-review


The present study was designed to assess the effect of orally administered fluoropyrimidine, UFT as a neoadjuvant chemotherapy for gastric cancer. Eleven patients with gastric cancer were treated with UFT at 300 ~ 600 mg/day for 8 ~ 30 days before surgery. The therapeutic response was evaluated according to the criteria by Japanese Research Society for Gastric Cancer Study. In 10 out of 11 patients the macroscopic response was evaluated and 2 CR, 2 PR, and 6 NC (2MR) were seen (40% response). The responses were seen in 3 patients administered UFT at 600 mg/day and one patient administered UFT at 300 mg/day. There were no responses in the patients received UFT at 400 mg/day. All the patients underwent gastrectomy, and the histological response was assessed in all 11 patients and the response the higher than grade 2 were seen in 4 patients (36% response). The side effects were not seen. These results suggest that UFT may be clinically, beneficial neoadjuvant chemotherapy for gastric cancer.

Original languageEnglish
Pages (from-to)1837-1848
Number of pages12
JournalJournal of Japan Society for Cancer Therapy
Issue number12
Publication statusPublished - 1993 Dec 1


  • UFT
  • gastric cancer
  • neoadjuvant chemotherapy

ASJC Scopus subject areas

  • Cancer Research


Dive into the research topics of 'Neoadjuvant chemotherapy for gastric cancer with UFT'. Together they form a unique fingerprint.

Cite this